Company discovered nanobodies against a second target in musculoskeletal disease.
Ablynx reached a second milestone in its collaboration with Procter & Gamble Pharmaceuticals (P&GP). The company discovered novel Nanobodies® against a second target for possible new treatments in the musculoskeletal area. The first milestone was achieved in December 2006.
As part of this on-going collaboration Ablynx is responsible for discovering nanobodies that meet an agreed product profile. P&GP is responsible for the pre-clinical and clinical development of Nanobodies®, as well as the commercialization of any resulting drug products.
